<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113135</article-id><article-id pub-id-type="publisher-id">ACM-40860</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_32372603.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  垂体腺瘤卒中的临床诊治进展
  Progress of Clinical Diagnosis and Treatment in Pituitary Apoplexy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>卓群</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>宇浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>宇翔</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>尹</surname><given-names>宏伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>照建</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院神经外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>939</fpage><lpage>946</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    垂体腺瘤卒中(Pituitary adenoma apoplexy, Pituitary apoplexy, PA)是垂体腺瘤因出血或者梗死而引起一系列神经和内分泌症状的一种临床综合征，分为出血性卒中和缺血性卒中。其发病机制复杂目前尚未完全阐明。由于垂体腺瘤卒中临床上少见，若不能早期诊断与治疗，可导致患者预后不良，增加并发症及死亡率。本文将结合国内外文献，对垂体腺瘤卒中的临床诊治进展予以简单分析。
    Pituitary apoplexy is a clinical syndrome with a series of neuroendocrine symptoms caused by bleeding or infarction of pituitary adenomas, and it is divided into hemorrhagic pituitary apoplexy and ischemic pituitary apoplexy. The pathogenesis of pituitary apoplexy is complex and has not been fully elucidated at present. Because pituitary apoplexy is rare in clinic, if it can’t be diagnosed and treated early, it can lead to poor prognosis and increase complications and mortality for patient. In this article, we will combine with the literature at home and abroad to briefly analyze the progress of clinical diagnosis and treatment of pituitary apoplexy. 
  
 
</p></abstract><kwd-group><kwd>垂体腺瘤，垂体腺瘤卒中，临床诊治, Pituitary Adenoma</kwd><kwd> Pituitary Apoplexy</kwd><kwd> Clinical Diagnosis and Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>垂体腺瘤卒中(Pituitary adenoma apoplexy, Pituitary apoplexy, PA)是垂体腺瘤因出血或者梗死而引起一系列神经和内分泌症状的一种临床综合征，分为出血性卒中和缺血性卒中。其发病机制复杂目前尚未完全阐明。由于垂体腺瘤卒中临床上少见，若不能早期诊断与治疗，可导致患者预后不良，增加并发症及死亡率。本文将结合国内外文献，对垂体腺瘤卒中的临床诊治进展予以简单分析。</p></sec><sec id="s2"><title>关键词</title><p>垂体腺瘤，垂体腺瘤卒中，临床诊治</p></sec><sec id="s3"><title>Progress of Clinical Diagnosis and Treatment in Pituitary Apoplexy<sup> </sup></title><p>Zhuoqun Li<sup>1</sup>, Yuhao Yang<sup>1</sup>, Yuxiang Wang<sup>1</sup>, Hongwei Yin<sup>1</sup>, Zhaojian Li<sup>2*</sup></p><p><sup>1</sup>Department of Medicine, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/18-1571981x4_hanspub.png" /></p><p>Received: Feb. 8<sup>th</sup>, 2021; accepted: Feb. 28<sup>th</sup>, 2021; published: Mar. 10<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/18-1571981x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Pituitary apoplexy is a clinical syndrome with a series of neuroendocrine symptoms caused by bleeding or infarction of pituitary adenomas, and it is divided into hemorrhagic pituitary apoplexy and ischemic pituitary apoplexy. The pathogenesis of pituitary apoplexy is complex and has not been fully elucidated at present. Because pituitary apoplexy is rare in clinic, if it can’t be diagnosed and treated early, it can lead to poor prognosis and increase complications and mortality for patient. In this article, we will combine with the literature at home and abroad to briefly analyze the progress of clinical diagnosis and treatment of pituitary apoplexy.</p><p>Keywords:Pituitary Adenoma, Pituitary Apoplexy, Clinical Diagnosis and Treatment</p><disp-formula id="hanspub.40860-formula11"><graphic xlink:href="//html.hanspub.org/file/18-1571981x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/18-1571981x8_hanspub.png" /> <img src="//html.hanspub.org/file/18-1571981x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>垂体腺瘤卒中是垂体腺瘤因出血或者梗死而引起一系列神经和内分泌症状的一种临床综合征，常表现为突然发作的头痛、视力下降、恶心呕吐、眼肌麻痹、脑膜刺激症及内分泌激素缺乏 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>]。1989年Bailey首次报道了一例垂体腺瘤合并出血的患者 [<xref ref-type="bibr" rid="hanspub.40860-ref3">3</xref>]，但直到1950年才被Brougham正式命名为垂体腺瘤卒中 [<xref ref-type="bibr" rid="hanspub.40860-ref4">4</xref>]。垂体腺瘤卒中分为垂体腺瘤出血性卒中和垂体腺瘤缺血性卒中，其中出血性卒中更为常见 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref5">5</xref>]。由于垂体腺瘤卒发病率较低，且大多数患者发病之前并未被诊断为垂体腺瘤，导致患者容易被误诊漏诊从而延误治疗。本文将从垂体腺瘤卒中的流行病学、发病机制、临床表现、影像学特点、诊断与鉴别诊断、治疗及预后等方面进行综述，以提高对该疾病的认识。</p></sec><sec id="s6"><title>2. 流行病学</title><p>由于目前垂体腺瘤卒中的分型标准没有得到统一，不同的文献报道的发病率差异较大。总体来说，垂体腺瘤发生卒中的概率约为2%~12%，高于其他颅内肿瘤，其中绝大部分为出血性卒中 [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref6">6</xref>]。有学者认为垂体腺瘤卒中以男性多发 [<xref ref-type="bibr" rid="hanspub.40860-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref8">8</xref>]，而有些学者的观点与之相反，认为发病并无明显的性别差异 [<xref ref-type="bibr" rid="hanspub.40860-ref9">9</xref>]。垂体腺瘤卒中的发病年龄主要集中在50~60岁的中老年人 [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref10">10</xref>]。相对于垂体微腺瘤，大腺瘤和巨大腺瘤更容易发生卒中 [<xref ref-type="bibr" rid="hanspub.40860-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref11">11</xref>]。所有的垂体腺瘤类型均可发生卒中。Wakai等人 [<xref ref-type="bibr" rid="hanspub.40860-ref12">12</xref>] 对560例垂体腺瘤患者和51例垂体腺瘤卒中患者进行研究分析，发现不同垂体腺瘤类型之间卒中发生率无显著性差异。然而，Randeva [<xref ref-type="bibr" rid="hanspub.40860-ref9">9</xref>] 等人与da Motta等人 [<xref ref-type="bibr" rid="hanspub.40860-ref11">11</xref>] 的研究表明，在充分考虑各型腺瘤所占构成比情况下，无功能腺瘤的卒中发生率高于其它类型腺瘤。无功能垂体腺瘤更容易发生卒中的可能机制是：由于肿瘤无内分泌功能，往往在晚期才出现压迫症状，因此在患者确诊时肿瘤体积更大，更容易发生梗死和(或)出血。</p></sec><sec id="s7"><title>3. 发病机制</title><p>垂体腺瘤发生卒中的机制尚存在争议，目前主要包括以下几个方面：</p><sec id="s7_1"><title>3.1. 内在因素</title><p>肿瘤的内在因素主要包括：1) 垂体腺瘤的血管生成有限，血管密度低，同时垂体腺瘤生长过快，导致其血液供应不足，从而引起肿瘤缺血、坏死，继之出血。2) 垂体腺瘤内血管形成不规则薄壁血窦，肿瘤体积增大引起局部压力增高，导致血管破裂出血。3) 肿瘤血管本身的脆性以及血管内发生动脉硬化性血栓栓塞。4) 垂体腺瘤向鞍上扩展，垂体上动脉和漏斗被挤压于鞍膈孔，导致肿瘤血运减少 [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref15">15</xref>]。</p></sec><sec id="s7_2"><title>3.2. 诱发因素</title><p>除了肿瘤的内在因素，外在因素的介入，如某些药物和手术治疗、病理状态可诱发垂体腺瘤卒中 [<xref ref-type="bibr" rid="hanspub.40860-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref16">16</xref>]。于是，有学者把诱发垂体腺瘤发生卒中的外部因素称为垂体腺瘤卒中的“诱发因素” [<xref ref-type="bibr" rid="hanspub.40860-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref14">14</xref>]。临床上约10%~40%的垂体腺瘤卒中患者存在诱发因素 [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>]。Biousse [<xref ref-type="bibr" rid="hanspub.40860-ref14">14</xref>] 等人将诱发因素分为四类：1) 高血压、剧烈活动等因素引起全身血流量急剧增加。2) 以心脏手术及骨科手术为代表的大手术引起全身血流量下降。3) 垂体动力学试验刺激腺垂体。4) 服用抗凝药、肝功能减退而导致凝血异常。相关文献已经报道了许多可能直接引发垂体卒中的诱发因素 [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref17">17</xref>]，例如：年龄，性别，头部外伤，骨科、心脏等大手术，高血压，糖尿病，服用抗血栓药物，溴隐亭治疗，放射治疗，垂体动态试验，妊娠，凝血疾病等。但是，这些诱发因素多以病例报告和病例系列的形式进行报道，目前尚缺少大样本资料的临床统计分析。</p></sec><sec id="s7_3"><title>3.3. 分子因素</title><p>目前关于垂体腺瘤卒中分子方面的研究较少。最近有学者认为体内遗传因子、细胞因子和生长因子之间的相互作用促进了垂体腺瘤卒中的发生，并通过对血管内皮生长因子(Vascular endothelial growth factor, VEGF)、肿瘤坏死因子-α (Tumor necrosis factor-α, TNF-α)、垂体瘤转化基因(Pituitary tumor transforming gene, PTTG)、基质金属蛋白酶-9 (Matrix metalloproteinase-9, MMP-9)和Ki-67等分子靶点的分析，提出了垂体腺瘤卒中可能的分子途径 [<xref ref-type="bibr" rid="hanspub.40860-ref18">18</xref>]。VEGF是一种同源二聚体有丝分裂糖蛋白，是目前促进肿瘤血管生成作用最强的细胞因子。基质金属蛋白酶(MMPs)是参与细胞外基质降解从而引起血管通透性的蛋白水解酶，在这一酶系中，MMP-9是最重要，也是研究最为广泛的侵袭因子之一。VEGF、MMP-9等因子在多种出血性疾病以及多种颅内肿瘤出血的发生发展过程中可能发挥了一定作用，但对于上述两种因子在卒中垂体瘤中的表达的研究结果差异较大 [<xref ref-type="bibr" rid="hanspub.40860-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref20">20</xref>]。PTTG与血管生成和血管内皮生长因子表达相关，在垂体细胞转化与肿瘤形成中起到了重要的作用 [<xref ref-type="bibr" rid="hanspub.40860-ref21">21</xref>]。PTTG可以激活成纤维细胞生长因子-2 (FGF-2)，激活的FGF-2进一步调节血管内皮细胞VEGF的表达，促进肿瘤血管生成 [<xref ref-type="bibr" rid="hanspub.40860-ref22">22</xref>]。TNF-α可以介导IL-8及其mRNA在细胞中稳定表达，而IL-8能够促进血管内皮细胞的增殖，这对于肿瘤内部新生血管的形成是非常关键的一步 [<xref ref-type="bibr" rid="hanspub.40860-ref23">23</xref>]。许多研究发现较高的Ki-67与垂体腺瘤的侵袭性和复发性有关 [<xref ref-type="bibr" rid="hanspub.40860-ref24">24</xref>]。尽管Ki-67在垂体腺瘤中的研究非常广泛，但目前关于Ki-67在垂体腺瘤卒中表达相关的研究很少，而且研究结果并不一致 [<xref ref-type="bibr" rid="hanspub.40860-ref18">18</xref>]。</p></sec></sec><sec id="s8"><title>4. 临床表现</title><p>垂体腺瘤出血和坏死会导致鞍内压力增加，进而会对邻近结构产生不同程度的压迫，产生头痛、视力视野障碍、眼肌麻痹、恶心呕吐和垂体功能低下等症状 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref25">25</xref>]。头痛是急性卒中最突出的症状，超过80%的患者出现头痛，通常表现为眶后头痛，但也可以是双额部头痛或弥漫性头痛 [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>]。肿瘤出血导致体积增加，对视神经、视交叉以及动眼神经等周围结构产生压迫，从而产生视力下降、视野缺损、眼肌麻痹等症状。据相关文献报道，50%~70%的卒中患者存在视力下降，30%的患者出现视野缺损，另外有10%的患者出现失明 [<xref ref-type="bibr" rid="hanspub.40860-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref12">12</xref>]。有些患者还会出现畏光、恶心、呕吐、发热等症状，容易误诊为脑膜炎。若垂体腺瘤卒中继发梗阻性脑积水，患者还可以出现不同程度的意识障碍 [<xref ref-type="bibr" rid="hanspub.40860-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref27">27</xref>]。垂体激素缺乏是垂体腺瘤卒中的另一大特征，特别是垂体前叶激素缺乏。几乎所有的PA患者都有生长激素缺乏，约50%~80%的患者会出现皮质醇缺乏，30%~70%和40%~75%的患者表现为甲状腺激素缺乏和性激素缺乏 [<xref ref-type="bibr" rid="hanspub.40860-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref27">27</xref>]。垂体腺瘤缺血性卒中可能具有独特的内分泌学特点。我们对26例垂体腺瘤缺血性卒中患者的垂体功能进行了评估，发现垂体腺瘤缺血性卒中最常发生垂体-性腺轴功能低下，其内分泌学特点为患者术前泌乳素和睾酮水平的急剧下降 [<xref ref-type="bibr" rid="hanspub.40860-ref28">28</xref>]。此外，临床上约25%~50%的患者无以上典型临床表现，但在影像学或组织病理学检查中可发现肿瘤出血的证据，因此被称为亚临床垂体腺瘤卒中(Subclinical pituitary adenoma apoplexy, SPAA) [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref29">29</xref>]，往往容易被忽略而延误诊断与治疗。</p><p>1995年王任直等 [<xref ref-type="bibr" rid="hanspub.40860-ref29">29</xref>] 根据肿瘤卒中后对周围结构的影响和病情缓急及严重程度将垂体腺瘤卒中患者分为四种类型：I型：暴发性垂体腺瘤卒中；II型：急性垂体腺瘤卒中；III型：亚急性垂体腺瘤卒中；IV型：慢性垂体腺瘤卒中(见表1)。其中对于III，IV型垂体腺瘤卒中因其临床表现多不典型或缺如又称为SPAA。2011年Rajasekaran [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] 等基于意识水平、视力、视野和眼外肌功能等临床症状提出了垂体卒中的评分标准(见表2)。以上对于临床医师进行治疗方案的选择以及判断患者的预后提供了帮助。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical classification of pituitary apoplexy [29</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分型</th><th align="center" valign="middle" >临床表现</th></tr></thead><tr><td align="center" valign="middle" >暴发性垂体腺瘤卒中</td><td align="center" valign="middle" >指出血迅猛，出血量大，直接影响下丘脑。此时，病人均伴有脑水肿及明显颅内压增高，出血后3 h内即出现明显视力视野障碍，意识障碍进行性加重，直到昏迷死亡。</td></tr><tr><td align="center" valign="middle" >急性垂体腺瘤卒中</td><td align="center" valign="middle" >指出血比较迅猛，出血量较大，已累及周围结构，但未影响下丘脑，也无明显脑水肿及颅内压增高。临床表现为头痛、视力视野障碍、眼肌麻痹或意识障碍，在出血后24 h内达到高峰。</td></tr><tr><td align="center" valign="middle" >亚急性垂体腺瘤卒中</td><td align="center" valign="middle" >出血较缓慢，出血量小，对周围组织结构影响较轻。可有头痛，视力视野障碍或肌肉麻痹，使原有垂体腺瘤症状轻度加重，无脑膜刺激征及意识障碍，常被病人忽略。</td></tr><tr><td align="center" valign="middle" >慢性垂体腺瘤卒中</td><td align="center" valign="middle" >出血量小，无周围组织结构受压表现，临床上除原有垂体腺瘤的表现外，无任何其他症状，往往是CT、MRI检查或手术时才发现。</td></tr></tbody></table></table-wrap><p>表1. 垂体腺瘤卒中的临床分型 [<xref ref-type="bibr" rid="hanspub.40860-ref29">29</xref>]</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Pituitary apoplexy score (PAS) [1</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床表现</th><th align="center" valign="middle" >分数</th></tr></thead><tr><td align="center" valign="middle" >意识水平</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >GCS评分：15分</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >GCS评分：8~14分</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >GCS评分：&lt;8分</td><td align="center" valign="middle" >4</td></tr><tr><td align="center" valign="middle" >视力</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >单侧受累</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >双侧受累</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >视野</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >单侧受累</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >双侧受累</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >眼外肌功能</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >正常</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >单侧受累</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >双侧受累</td><td align="center" valign="middle" >2</td></tr></tbody></table></table-wrap><p>表2. 垂体卒中评分 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>]</p></sec><sec id="s9"><title>5. 影像学特点</title><p>由于垂体腺瘤卒中的病理学特征主要表现为：单纯性出血、单纯性梗死、出血合并梗死，其中单纯性出血和单纯性梗死少见，以出血合并梗死多见，所以影像学上主要表现为出血合并梗死的混合特征 [<xref ref-type="bibr" rid="hanspub.40860-ref3">3</xref>]。垂体腺瘤出血性卒中在CT上多表现为鞍区高密度或等高密度影。MRI通常为T1WI等信号内合并高信号，其中瘤组织为等信号，出血或呈暗褐色泥沙样改变的肿瘤组织为T1WI高信号；陈旧血、血凝块多为T1WI高信号，T2WI为高信号或等、高混杂信号，少数陈旧性血为低信号 [<xref ref-type="bibr" rid="hanspub.40860-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref30">30</xref>]。瘤内出血可以位于肿瘤中心，也可位于鞍内、鞍上或整个鞍区。对于坏死、囊变，T1WI为低信号，T2WI为高信号。其中，囊变多表现为边缘光滑，部分囊壁在T1WI上还表现为高信号，可能是由于其周边有较多的新生肉芽组织和毛细血管所致 [<xref ref-type="bibr" rid="hanspub.40860-ref31">31</xref>]。另外，Arita等人 [<xref ref-type="bibr" rid="hanspub.40860-ref32">32</xref>] 首次发现，急性期垂体腺瘤卒中患者的蝶窦黏膜增厚，以蝶鞍下方最为明显，可能是由于蝶窦黏膜上皮层肿胀所致。值得注意的是，蝶窦黏膜增厚并不表示感染性鼻窦炎，也不是经蝶窦手术的禁忌证。垂体腺瘤缺血性卒中在CT及MRI平扫缺乏诊断的特异性，但是我们通过研究发现，在垂体动态增强MRI上，肿瘤周边“环形强化征”伴瘤内斑片状强化的影像学特点具有极其重要的诊断价值 [<xref ref-type="bibr" rid="hanspub.40860-ref33">33</xref>]。</p></sec><sec id="s10"><title>6. 诊断与鉴别诊断</title><p>国内外学者根据患者的临床表现、病史、影像学表现、术中所见等方面提出了垂体腺瘤卒中的诊断标准 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref29">29</xref>]。首先，关于急性垂体腺瘤卒中的诊断标准：1) 病程中有突发头痛恶心呕吐和(或)视觉障碍，眼外肌麻痹和意识改变等病史；2) CT和(或)MRI检查提示垂体肿瘤，密度和(或)信号不均匀；3) 术中证实垂体瘤内有陈旧性出血。其次，关于亚临床垂体腺瘤卒中的诊断标准：1) 病程中除原有垂体腺瘤的临床表现外，无急性垂体腺瘤卒中病史；2) CT和(或)MRI检查提示垂体肿瘤，密度和(或)信号不均匀；3) 术中证实垂体瘤内有陈旧性出血。以上标准主要适用于出血性卒中以及出血合并缺血性卒中，对于单纯缺血性卒中，由于临床罕见，其诊断依据目前尚未达成共识。我们认为，对于动态增强或增强MRI提示垂体腺瘤瘤周环形强化伴瘤内斑片状强化，内分泌检查提示泌乳素及睾酮水平急剧下降的患者，应高度怀疑垂体腺瘤缺血性卒中 [<xref ref-type="bibr" rid="hanspub.40860-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref33">33</xref>]。结合上述垂体腺瘤卒中的诊断标准，对于发生卒中前已经出现垂体腺瘤的症状的患者，诊断并不困难。而对于发病之前无症状的患者不易立即做出诊断，易被误诊为脑膜炎、蛛网膜下腔出血等疾病。因此，任何疑似垂体腺瘤卒中的患者，除了进行影像学检查外，还应对患者进行全面的神经系统查体，并对包括所有垂体激素在内的实验室指标进行全面分析，从而最大程度地避免误诊与漏诊。</p></sec><sec id="s11"><title>7. 治疗与预后</title><p>对于垂体腺瘤卒中采取保守治疗或手术治疗，目前意见尚不一致 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref27">27</xref>]。一般情况下，对头痛症状轻微、无视觉症状、无意识改变或有严重合并症的患者通常采取保守治疗；而对有明显视觉症状，意识改变，神经系统状况迅速恶化的患者采取手术治疗。无论采取何种治疗方式，对于出现垂体功能低下的患者，早期给予激素替代治疗是关键 [<xref ref-type="bibr" rid="hanspub.40860-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref27">27</xref>]。由于皮质激素缺乏可导致急性肾上腺功能不全，威胁病人生命，因此对所有怀疑垂体腺瘤卒中的病人都应适当补充类固醇激素，提高机体的应激反应能力 [<xref ref-type="bibr" rid="hanspub.40860-ref28">28</xref>]。部分学者认为垂体腺瘤卒中后可自愈，特别是不伴有明显视觉或其他神经功能障碍者，自愈的可能性更大，因此主张保守治疗 [<xref ref-type="bibr" rid="hanspub.40860-ref34">34</xref>]。而对于出现意识障碍、视力迅速下降的患者，如果在症状出现后24小时至72小时内到医院就诊，都应行急症手术进行减压 [<xref ref-type="bibr" rid="hanspub.40860-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref27">27</xref>]。Mehmet等 [<xref ref-type="bibr" rid="hanspub.40860-ref35">35</xref>] 认为，在卒中后6天到8天内接受早期手术患者的视力视野改善更明显。对于发生卒中的垂体腺瘤，肿瘤往往质地较软，并且内部有出血和坏死，更加易于切除。而神经内镜可以提供良好的照明，具有视角大、可近距离观察的优点，能够更清晰地显示深部结构。因此，大多数学者认为垂体腺瘤卒中手术应首选神经内镜下经蝶入路，与开颅手术相比，具有创伤小、并发症少、术后恢复快等优点。Dubuission等 [<xref ref-type="bibr" rid="hanspub.40860-ref10">10</xref>] 认为神经内镜下经蝶手术不仅可以改善患者的视力、视野，降低卒中的致残率和死亡率，而且还可以改善卒中后垂体功能低下。</p><p>无论是保守治疗还是手术治疗，多数患者的视力水平在治疗后都有显著改善 [<xref ref-type="bibr" rid="hanspub.40860-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref36">36</xref>]。经手术治疗后，74%到94%的患者视野和(或)视力缺陷较术前有所改善，68%到100%的患者眼肌麻痹症状改善 [<xref ref-type="bibr" rid="hanspub.40860-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40860-ref37">37</xref>]。由于大多数患者术前存在不同程度的垂体功能障碍，术后垂体功能低下的改善率从12%到23%不等，患者需要长期的激素替代治疗 [<xref ref-type="bibr" rid="hanspub.40860-ref36">36</xref>]。Ayuk等人 [<xref ref-type="bibr" rid="hanspub.40860-ref27">27</xref>] 的研究表明，保守治疗和手术治疗对卒中患者垂体功能低下的改善率并无显著差异。对于垂体腺瘤卒中患者保守治疗与手术治疗的远期疗效，还需进一步研究随访。有一点可以肯定的是，无论采取何种治疗方式，定期复查MRI和垂体内分泌激素仍是必要的。</p></sec><sec id="s12"><title>8. 总结与展望</title><p>综上，垂体腺瘤卒中是一种表现为严重头痛、视力丧失、眼肌麻痹和垂体功能减退的临床综合征，排除已知的垂体腺瘤卒中诱发因素至关重要。垂体腺瘤卒中治疗方式的选择取决于症状的严重程度和发病时间。对于存在意识障碍、视力下降及垂体功能低下的急性垂体腺瘤卒中，应首选内镜手术治疗。垂体腺瘤卒中的发病机制目前尚未明确，可能有多种机制共同参与了垂体腺瘤卒中的发生。体内未知的基因、细胞因子、蛋白质可能参与了垂体卒中的出血和梗死的发病过程，未来需要进行基因组学、蛋白质组学和代谢组学等方面研究。此外，还需纳入大样本的临床资料，研究分析垂体腺瘤卒中的诱发因素。通过以上两方面的研究，我们可以进一步探究垂体腺瘤卒中的发病机制，继而采取一系列措施以降低垂体腺瘤发生卒中的风险。</p></sec><sec id="s13"><title>文章引用</title><p>李卓群,杨宇浩,王宇翔,尹宏伟,李照建. 垂体腺瘤卒中的临床诊治进展Progress of Clinical Diagnosis and Treatment in Pituitary Apoplexy[J]. 临床医学进展, 2021, 11(03): 939-946. https://doi.org/10.12677/ACM.2021.113135</p></sec><sec id="s14"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40860-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rajasekaran, S., Vanderpump, M., Baldeweg, S., et al. (2011) UK Guidelines for the Management of Pituitary Apoplexy. Clinical Endocrinology, 74, 9-20. &lt;br&gt;https://doi.org/10.1111/j.1365-2265.2010.03913.x</mixed-citation></ref><ref id="hanspub.40860-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Briet, C., Salenave, S., Bonneville, J.-F., Laws, E.R. and Chanson, P. (2015) Pituitary Apoplexy. Endocrine Reviews, 36, 622-645. &lt;br&gt;https://doi.org/10.1210/er.2015-1042</mixed-citation></ref><ref id="hanspub.40860-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Pal, A., Capatina, C., Tenreiro, A.P., et al. (2011) Pituitary Apoplexy in Non-Functioning Pituitary Adenomas: Long Term Follow Up Is Important Because of Significant Numbers of Tumour Recurrences. Clinical Endocrinology, 75, 501-504. &lt;br&gt;https://doi.org/10.1111/j.1365-2265.2011.04068.x</mixed-citation></ref><ref id="hanspub.40860-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Brougham, M., Heusner, A.P. and Adams, R.D. (1950) Acute Degenerative Changes in Adenomas of the Pituitary Body—With Special Reference to Pituitary Apoplexy. Journal of Neurosurgery, 7, 421-439.  
&lt;br&gt;https://doi.org/10.3171/jns.1950.7.5.0421</mixed-citation></ref><ref id="hanspub.40860-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wildemberg, L.E., Glezer, A., Bronstein, M.D. and Gadelha, M.R. (2018) Apoplexy in Nonfunctioning Pituitary Adenomas. Pituitary, 21, 138-144. &lt;br&gt;https://doi.org/10.1007/s11102-018-0870-x</mixed-citation></ref><ref id="hanspub.40860-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Barkhoudarian, G. and Kelly, D.F. (2019) Pituitary Apoplexy. Neurosurgery Clinics of North America, 30, 457-463.  
&lt;br&gt;https://doi.org/10.1016/j.nec.2019.06.001</mixed-citation></ref><ref id="hanspub.40860-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Möller-Goede, D.L., Brändle, M., Landau, K., et al. (2011) Pituitary Apoplexy: Re-Evaluation of Risk Factors for Bleeding into Pituitary Adenomas and Impact on Outcome. European Journal of Endocrinology, 164, 37-43.  
&lt;br&gt;https://doi.org/10.1530/EJE-10-0651</mixed-citation></ref><ref id="hanspub.40860-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Giammattei, L., Mantovani, G., Carrabba, G., et al. (2016) Pituitary Apoplexy: Considerations on a Single Center Experience and Review of the Literature. Journal of Endocrinological Investigation, 39, 739-746.  
&lt;br&gt;https://doi.org/10.1007/s40618-015-0424-2</mixed-citation></ref><ref id="hanspub.40860-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Randeva, H.S., Schoebel, J., Byrne, J., Esiri, M., Adams, C.B.T. and Wass, J.A.H. (1999) Classical Pituitary Apoplexy: Clinical Features, Management and Outcome. Clinical Endocrinology, 51, 181-188.  
&lt;br&gt;https://doi.org/10.1046/j.1365-2265.1999.00754.x</mixed-citation></ref><ref id="hanspub.40860-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Dubuisson, A.S., Beckers, A. and Stevenaert, A. (2007) Classical Pituitary Tumour Apoplexy: Clinical Features, Management and Outcomes in a Series of 24 Patients. Clinical Neurology and Neurosurgery, 109, 63-67.  
&lt;br&gt;https://doi.org/10.1016/j.clineuro.2006.01.006</mixed-citation></ref><ref id="hanspub.40860-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">da Motta, L.A., de Mello, P.A., de Lacerda, C.M., Neto, A.P., da Motta, L.D. and Filho, M.F. (1999) Pituitary Apoplexy. Clinical Course, Endocrine Evaluations and Treatment Analysis. Journal of Neurosurgical Sciences, 43, 25-36.</mixed-citation></ref><ref id="hanspub.40860-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wakai, S., Fukushima, T., Teramoto, A. and Sano, K. (1981) Pituitary Apoplexy: Its Incidence and Clinical Significance. Journal of Neurosurgery, 55, 187-193. &lt;br&gt;https://doi.org/10.3171/jns.1981.55.2.0187</mixed-citation></ref><ref id="hanspub.40860-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Jane, J.A., Semple, P.L. and Laws, E.R. (2007) Clinical Relevance of Precipitating Factors in Pituitary Apoplexy. Neurosurgery, 61, 956-961. &lt;br&gt;https://doi.org/10.1227/01.neu.0000303191.57178.2a</mixed-citation></ref><ref id="hanspub.40860-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Biousse, V., Newman, N.J. and Oyesiku, N.M. (2001) Precipitating Factors in Pituitary Apoplexy. Journal of Neurology, Neurosurgery &amp; Psychiatry, 71, 542-545. &lt;br&gt;https://doi.org/10.1136/jnnp.71.4.542</mixed-citation></ref><ref id="hanspub.40860-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Naito, Y., Mori, J., Tazoe, J., et al. (2019) Pituitary Apoplexy after Cardiac Surgery in a 14-Year-Old Girl with Carney Complex: A Case Report. Endocrine Journal, 66, 1117-1123. &lt;br&gt;https://doi.org/10.1507/endocrj.EJ19-0183</mixed-citation></ref><ref id="hanspub.40860-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Khandelwal, M., et al. (2005) Pituitary Apoplexy Following Bilateral Total Knee Arthroplasty. Postgraduate Medicine, 51, 155-156.</mixed-citation></ref><ref id="hanspub.40860-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, F.U., Pandey, P. and Mahapatra, A.K. (2005) Post Operative “Pituitary Apoplexy” in Giant Pituitary Adenomas: A Series of Cases. Neurology India, 53, 236-238. &lt;br&gt;https://doi.org/10.4103/0028-3886.16933</mixed-citation></ref><ref id="hanspub.40860-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Gupta, P. and Dutta, P. (2018) Landscape of Molecular Events in Pituitary Apoplexy. Frontiers in Endocrinology, 9, 107. &lt;br&gt;https://doi.org/10.3389/fendo.2018.00107</mixed-citation></ref><ref id="hanspub.40860-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Xiao, Z., Liu, Q., Mao, F., et al. (2011) TNF-Alpha-Induced VEGF and MMP-9 Expression Promotes Hemorrhagic Transformation in Pituitary Adenomas. International Journal of Molecular Sciences, 12, 4165-4179.  
&lt;br&gt;https://doi.org/10.3390/ijms12064165</mixed-citation></ref><ref id="hanspub.40860-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mccoll, B.W., Rose, N., Robson, F.H., et al. (2010) Increased Brain Microvascular MMP-9 and Incidence of Haemorrhagic Transformation in Obese Mice after Experimental Stroke. Journal of Cerebral Blood Flow &amp; Metabolism, 30, 267-272. &lt;br&gt;https://doi.org/10.1038/jcbfm.2009.217</mixed-citation></ref><ref id="hanspub.40860-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Pei, L. and Melmed, S. (1997) Isolation and Characterization of a Pituitary Tumor Transforming Gene (PTTG). Molecular Endocrinology, 11, 433-441. &lt;br&gt;https://doi.org/10.1210/mend.11.4.9911</mixed-citation></ref><ref id="hanspub.40860-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ishikawa, H., Heaney, A.P., Yu, R., Horwitz, G.A. and Melmed, S. (2001) Human Pituitary Tumor-Transforming Gene Induces Angiogenesis. The Journal of Clinical Endocrinology &amp; Metabolism, 86, 867-874.  
&lt;br&gt;https://doi.org/10.1210/jc.86.2.867</mixed-citation></ref><ref id="hanspub.40860-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Berry, K.K., Varney, M.L., Dave, B.J., et al. (2001) Expression of Interleukin-8 in Human Metastatic Endometrial Carcinoma Cells and Its Regulation by Inflammatory Cytokines. International Journal of Gynecological Cancer, 11, 54-60. &lt;br&gt;https://doi.org/10.1046/j.1525-1438.2001.011001054.x</mixed-citation></ref><ref id="hanspub.40860-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Salehi, F., Agur, A., Scheithauer, B.W., Kovacs, K., Lloyd, R.V. and Cusimano, M. (2009) Ki-67 in Pituitary Neoplasms: A Review Part I. Neurosurgery, 65, 429-437. &lt;br&gt;https://doi.org/10.1227/01.NEU.0000349930.66434.82</mixed-citation></ref><ref id="hanspub.40860-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Verrees, M., Arafah, B.M. and Selman, W.R. (2004) Pituitary Tumor Apoplexy: Characteristics, Treatment, and Outcomes. Neurosurgical Focus, 16, E6. &lt;br&gt;https://doi.org/10.3171/foc.2004.16.4.7</mixed-citation></ref><ref id="hanspub.40860-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Bujawansa, S., Thondam, S.K., Steele, C., et al. (2014) Presentation, Management and Outcomes in Acute Pituitary Apoplexy: A Large Single-Centre Experience from the United Kingdom. Clinical Endocrinology, 80, 419-424.  
&lt;br&gt;https://doi.org/10.1111/cen.12307</mixed-citation></ref><ref id="hanspub.40860-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ayuk, J., McGregor, E.J., Mitchell, R.D. and Gittoes, N.J. (2004) Acute Management of Pituitary Apoplexy-Surgery or Conservative Management? Clinical Endocrinology, 61, 747-752. &lt;br&gt;https://doi.org/10.1111/j.1365-2265.2004.02162.x</mixed-citation></ref><ref id="hanspub.40860-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">尹宏伟, 李卓群, 王宇翔, 等. 垂体腺瘤梗塞型卒中患者术前内分泌学特征初探[J]. 中华神经医学杂志, 2020, 19(6): 552-556.</mixed-citation></ref><ref id="hanspub.40860-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">王任直, 任祖渊, 苏长保, 等. 垂体腺瘤卒中的诊断和治疗(附49例报告) [J]. 中华神经外科杂志, 1995, 11(5): 255-258.</mixed-citation></ref><ref id="hanspub.40860-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">姚刚, 郭依廷. 垂体瘤卒中的MRI影像学表现分析[J]. 中国中西医结合影像学杂志, 2011, 9(2): 118-119+125.</mixed-citation></ref><ref id="hanspub.40860-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tosaka, M., Sato, N., Hirato, J., et al. (2007) Assessment of Hemorrhage in Pituitary Macroadenoma by T2*-Weighted Gradient-Echo MR Imaging. American Journal of Neuroradiology, 10, 2023-2029. &lt;br&gt;https://doi.org/10.3174/ajnr.A0692</mixed-citation></ref><ref id="hanspub.40860-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Arita, K., Kurisu, K., Tominaga, A., et al. (2001) Thickening of Sphenoid Sinus Mucosa during the Acute Stage of Pituitary Apoplexy. Neurosurgery, 95, 897-901. &lt;br&gt;https://doi.org/10.3171/jns.2001.95.5.0897</mixed-citation></ref><ref id="hanspub.40860-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">尹宏伟, 李环廷, 李卓群, 等. 垂体腺瘤梗死性卒中MRI影像学特征初步研究[J]. 中国微侵袭神经外科杂志, 2020, 25(7): 310-313.</mixed-citation></ref><ref id="hanspub.40860-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Pelkonen, R., Kuusisto, A., Salmi, J., et al. (1978) Pituitary Function after Pituitary Apoplexy. The American Journal of Medicine, 65, 773-778. &lt;br&gt;https://doi.org/10.1016/0002-9343(78)90795-7</mixed-citation></ref><ref id="hanspub.40860-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Turgut, M., Özsunar, Y., Başak, S., Guney, E., Kır, E. and Meteoğlu, İ. (2010) Pituitary Apoplexy: An Overview of 186 Cases Published during the Last Century. Acta Neurochirurgica, 152, 749-761.  
&lt;br&gt;https://doi.org/10.1007/s00701-009-0595-8</mixed-citation></ref><ref id="hanspub.40860-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Barkhoudarian, G. and Kelly, D.F. (2019) Pituitary Apoplexy. Neurosurgery Clinics of North America, 30, 457-463.  
&lt;br&gt;https://doi.org/10.1016/j.nec.2019.06.001</mixed-citation></ref><ref id="hanspub.40860-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Semple, P., Webb, M., de Villiers, J., et al. (2005) Pituitary Apoplexy. Neurosurgery, 56, 65-73.  
&lt;br&gt;https://doi.org/10.1227/01.NEU.0000144840.55247.38</mixed-citation></ref></ref-list></back></article>